NH SPAC 2 (206640) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NH SPAC 2 (206640) has a cash flow conversion efficiency ratio of 0.043x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩10.46 Billion ≈ $7.09 Million USD) by net assets (₩244.18 Billion ≈ $165.48 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of NH SPAC 2 to measure how many days the company can operate on defensive assets alone.
NH SPAC 2 - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how NH SPAC 2's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NH SPAC 2 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NH SPAC 2 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KHVATEC Co.Ltd
KQ:060720
|
0.116x |
|
Trabzonspor Sportif Yatirim ve Futbol Isletmeciligi Ticaret AS
IS:TSPOR
|
0.651x |
|
Samjin Pharm
KO:005500
|
-0.005x |
|
SPML Infra Limited
NSE:SPMLINFRA
|
-0.023x |
|
Southern Petrochemicals Industries Corporation Limited
NSE:SPIC
|
0.592x |
|
Daios Plastics S.A.
AT:DAIOS
|
N/A |
|
POLARIS RENEWABLE ENERGY
F:N4T
|
N/A |
|
Gordon Auto Body Parts Co Ltd
TW:1524
|
0.088x |
Annual Cash Flow Conversion Efficiency for NH SPAC 2 (2015–2025)
The table below shows the annual cash flow conversion efficiency of NH SPAC 2 from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of NH SPAC 2.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩244.18 Billion ≈ $165.48 Million |
₩22.08 Billion ≈ $14.96 Million |
0.090x | -18.92% |
| 2024-12-31 | ₩223.05 Billion ≈ $151.16 Million |
₩24.88 Billion ≈ $16.86 Million |
0.112x | -35.80% |
| 2023-12-31 | ₩197.42 Billion ≈ $133.79 Million |
₩34.30 Billion ≈ $23.24 Million |
0.174x | +23.18% |
| 2022-12-31 | ₩163.56 Billion ≈ $110.84 Million |
₩23.07 Billion ≈ $15.63 Million |
0.141x | -57.32% |
| 2021-12-31 | ₩151.09 Billion ≈ $102.39 Million |
₩49.93 Billion ≈ $33.83 Million |
0.330x | -11.28% |
| 2020-12-31 | ₩119.86 Billion ≈ $81.23 Million |
₩44.64 Billion ≈ $30.25 Million |
0.372x | +58.88% |
| 2019-12-31 | ₩73.55 Billion ≈ $49.84 Million |
₩17.24 Billion ≈ $11.68 Million |
0.234x | +188.18% |
| 2018-12-31 | ₩65.33 Billion ≈ $44.27 Million |
₩5.31 Billion ≈ $3.60 Million |
0.081x | +522.67% |
| 2017-12-31 | ₩67.87 Billion ≈ $46.00 Million |
₩886.74 Million ≈ $600.93K |
0.013x | -91.67% |
| 2016-12-31 | ₩75.17 Billion ≈ $50.94 Million |
₩11.79 Billion ≈ $7.99 Million |
0.157x | -3.10% |
| 2015-12-31 | ₩59.50 Billion ≈ $40.32 Million |
₩9.63 Billion ≈ $6.53 Million |
0.162x | -- |
About NH SPAC 2
Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testi… Read more